anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,146,155. Hair lacquers. MITSUBISHI RAYON CO. Ltd. and GOO CHEMICAL INDUSTRY CO. Ltd. 21 March, 1966 [26 March, 1965], No. 12291/66. Heading A5B. [Also in Divisions C3 and C4] A hair lacquer composition comprises (A) a resinous composition composed of a copolymer of (1) 5 to 40% by weight of an ester of a C 8  to C 18 -aliphatic alcohol and acrylic or methacrylic acid, (2) 6 to 35% of acrylic or methacrylic acid, and (3) 25 to 89 % of a monomer of formula wherein X is a hydrogen atom or methyl group and Y is a C 2  to C 5 -acyloxy or alkoxycarbonyl group, an amide group or a phenyl group, said copolymer having been neutralised or partially neutralised with a watersoluble base added to the copolymer in an amount of at least 60 mol per cent of the carboxyl group content of the copolymer, said resinous composition being in solution in (B) water and/or a water-soluble organic solvent. The composition may also contain lanolin and/or a perfume, or a spraying agent e.g. a halogenated hydrocarbon or liquefied petroleum gas may be added to form an aerosol composition. In these embodiments, Y may also be a nitrile group. Specified monomers (1) are 2-ethylhexyl acrylate and methacrylate and dodecyl acrylate and methacrylate. Monomer (3) is e.g. styrene, vinyl toluene, nbutylacrylate, ethylacrylate or methacrylate, or vinylacetate. In Example 1, 2-ethylhexyl acrylate, acrylic acid, methacrylic acid, ethylacrylate and styrene are copolymerised in ethanol and KOH is added to the solution formed before it is mixed with lanolin, perfume, trichloromonofluoromethane and dichloromonofluoromethane. A copolymer of dodecyl methacrylate, dodecyl acrylate acrylic acid, methacrylic acid, n-butyl acrylate and ethyl methacrylate is formed in Example 2 in solution in ethanol/isopropanol. The solution is neutralised with KOH and morpholine and polyethylene glycol, perfume and liquefied petroleum gas are added.
Before the procedure, the patient was placed in the left lateral position and a Quadratus Lumborum Block was applied at the thoracic 8-10 level. A total of 20 cc blocking fluid consisting of 14 cc of 0.5% bupivacaine and 6 cc of 2% lidocaine was used for the block. A minimum of 30 minutes was waited after the block. 2 mg of intravenous midazolam was administered before being taken to the operating room. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and intravenous 0.1-1 mcg/kg remifentanil was administered when the Vizel analog score was \> 4. Postoperatively, 1 g of paracetamol was routinely administered. When the Vizel analog score was \> 4, 50 mg of dexketoprofen was administered as a rescue analgesic. Postoperative 2nd, 6th, 12th and 24th hour visual analog scores of the patients were recorded.
Fluticasone Propionate/Salmeterol MDPI should not be initiated in patients during rapidly deteriorating or potentially life‑threatening episodes of asthma. Fluticasone Propionate/Salmeterol MDPI has not been studied in subjects with acutely deteriorating asthma. The initiation of Fluticasone Propionate/Salmeterol MDPI in this setting is not appropriate.

Serious acute respiratory events, including fatalities, have been reported when salmeterol, a component of this product, has been initiated in patients with significantly worsening or acutely deteriorating asthma. In most cases, these have occurred in patients with severe asthma (e.g., patients with a history of corticosteroid dependence, low pulmonary function, intubation, mechanical ventilation, frequent hospitalizations, previous life‑threatening acute asthma exacerbations) and in some patients with acutely deteriorating asthma (e.g., patients with significantly increasing symptoms; increasing need for inhaled, short‑acting beta2‑agonists; decreasing response to usual medications; increasing need for systemic corticosteroids; recent emergency room visits; deteriorating lung function). However, these events have occurred in a few patients with less severe asthma as well. It was not possible from these reports to determine whether salmeterol contributed to these events.

Increasing use of inhaled, short‑acting beta2‑agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. Patients should not use more than 1 inhalation twice daily of Fluticasone Propionate/Salmeterol MDPI.

Fluticasone Propionate/Salmeterol MDPI should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short‑acting beta2‑agonist, not Fluticasone Propionate/Salmeterol MDPI, should be used to relieve acute symptoms such as shortness of breath. When prescribing Fluticasone Propionate/Salmeterol MDPI, the healthcare provider should also prescribe an inhaled, short‑acting beta2-agonist (e.g., albuterol) for treatment of acute symptoms, despite regular twice‑daily use of Fluticasone Propionate/Salmeterol MDPI.

When beginning treatment with Fluticasone Propionate/Salmeterol MDPI, patients who have been taking oral or inhaled, short‑acting beta2‑agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.
Substd. 2-aminoethanols of the formula (I) and their salts are new. R is methyl, methoxy, F, Cl or Br and m is 0-3, but (i) if m is zero, then R is 2-, 3- or 4-methyl, 4-F, 4-Cl, 4-Br or 4-methoxy and the basic side chain is bonded to the salicylamide radical in the 4-position to the OH gp., or, if m is zero and R is 4-methyl, that side chain is bonded in the 4-position to the carbamoyl gp., and (ii) if m is 3 then R is 2-methoxy and the said side chain is bonded in the 4-position to the OH gp. (I) have use in the treatment of reactive or endogenous depressions of different degrees of severity, and also neurotic and other psychotropic disorders with lack of drive and depressive psychoses. They are also in some instances beta-receptor blockers, useful in the treatment of Angina pectoris and cardia rhythm disorders and as agents for reducing blood pressure; while in other instances they are cardiac beta-receptor stimulators and may be used for the treatment of insufficient cardiac output and for the treatment of asthma and circulatory disorders. Compsns. contg. (I) are conventional.
1,175,967. Photo-electric turbidometers. MARCHON PRODUCTS Ltd. Oct. 9, 1967 [Oct. 14, 1966], No.9187/68. Divided out of 1,175, 966. Heading G1A. The sulphate ion concentration of a solution is determined by passing the solution, free from suspended solids, together with a solution containing barium ions into a mixing chamber designed to inhibit the adherence of barium sulphate, passing the mixed solutions to a turbidimetric cell, illuminating the mixture in the turbidimetric cell and measuring the ratio of the amount of light transmitted through the mixture to the amount of light scattered therefrom. A metered quantity of a sample extracted from a wet process phosphoric acid reactor by the method disclosed in Specification 1,175, 966 is diluted with a measured quantity of water and mixed with a measured quantity of barium chloride in a mixing chamber. The mixing chamber is made of P. T. F. E. or provided with ultrasonic vibration to prevent adherence of barium sulphate. The amount of barium sulphate precipitated is measured in a turbidometer in which light is alternately passed along paths at 90 degrees to one another and a photo-cell measures the ratio of the transmitted to scattered light. The light beams may be derived from a common source and may be modulated by a rotating chopper.
DEMSER inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.

In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of 1 to 4 grams of DEMSER per day has reduced catecholamine biosynthesis from about 35% to 80% as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after DEMSER is discontinued. In some patients the total excretion of catecholamines and catecholamine metabolites may be lowered to normal or near normal levels (less than 10 mg/24 hours). In most patients, the duration of treatment has been two to eight weeks, but several patients have received DEMSER for periods of 1 to 10 years. 

Most patients with pheochromocytoma treated with DEMSER experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with DEMSER; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.

Metyrosine is well absorbed from the gastrointestinal tract. From 53% to 88% (mean 69%) was recovered in the urine as unchanged drug following maintenance oral doses of 600 to 4000 mg/24 hours in patients with pheochromocytoma or essential hypertension. Less than 1% of the dose was recovered as catechol metabolites. These metabolites are probably not present in sufficient amounts to contribute to the biochemical effects of metyrosine. The quantities excreted, however, are sufficient to interfere with accurate determination of urinary catecholamines determined by routine techniques.

Plasma half-life of metyrosine determined over an 8-hour period after single oral doses was 3-3.7 hours in three patients.

For further information, refer to: Sjoerdsma A, Engelman K, Waldman TA, Cooperman LH, Hammond WG. Pheochromocytoma: Current Concepts of Diagnosis and Treatment: Combined Clinical Staff Conference at the National Institutes of Health. Ann Intern Med. 1966;65:1302-1326.
Long-term dietary studies in mice and rats were conducted to evaluate the carcinogenic potential of bepotastine besilate. Bepotastine besilate did not significantly induce neoplasms in mice receiving a nominal dose of up to 200 mg/kg/day for 21 months or rats receiving a nominal dose of up to 97 mg/kg/day for 24 months. These dose levels represent systemic exposures approximating 350 and 200 times that achieved with human topical ocular use.

The no observable adverse effect levels for bepotastine besilate based on nominal dose levels in carcinogenicity tests were 18.7 to 19.9 mg/kg/day in mice and 9.6 to 9.8 mg/kg/day in rats (representing exposure margins of approximately 60 and 20 times the systemic exposure anticipated for topical use in humans).

There was no evidence of genotoxicity in the Ames test, in CHO cells (chromosome aberrations), in mouse hepatocytes (unscheduled DNA synthesis), or in the mouse micronucleus test.

When oral bepotastine was administered to male and female rats at doses up to 1,000 mg/kg/day, there was a slight reduction in fertility index and surviving fetuses. Infertility was not seen in rats given 200 mg/kg/day oral bepotastine besilate (approximately 3,300 times the systemic concentration anticipated for topical ocular use in humans).
Inject epinephrine intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. When administering to a child, to minimize the risk of injection related injury, hold the leg firmly in place and limit movement prior to and during an injection. The injection may be repeated every 5 to 10 minutes as necessary. For intramuscular administration, use a needle long enough (at least 1/2 inch to 5/8 inch) to ensure the injection is administered into the muscle. Monitor the patient clinically for the severity of the allergic reaction and potential cardiac effects of the drug, with repeat doses titrated to effect. Do not administer repeated injections at the same site, as the resulting vasoconstriction may cause tissue necrosis.

Adults and Children 30 kg (66 lbs) or more: 0.3 to 0.5 mg (0.3 mL to 0.5 mL) of undiluted epinephrine administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, up to a maximum of 0.5 mg (0.5 mL) per injection, repeated every 5 to 10 minutes as necessary. Monitor clinically for reaction severity and cardiac effects. 

Children less than 30 kg (66 lbs): 0.01 mg/kg (0.01 mL/kg) of undiluted epinephrine administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, up to a maximum of 0.3 mg (0.3 mL) per injection, repeated every 5 to 10 minutes as necessary. Monitor clinically for reaction severity and cardiac effects.
Oxygen pressure plays an integral role in regulating various aspects of cellular biology. Cell metabolism, proliferation, morphology, senescence, metastasis, and angiogenesis are some instances that are affected by different tensions of oxygen. Hyperoxia or high oxygen concentration, enforces the production of reactive oxygen species (ROS) that disturbs physiological homeostasis, and consequently, in the absence of antioxidants, cells and tissues are directed to an undesired fate. On the other side, hypoxia or low oxygen concentration, impacts cell metabolism and fate strongly through inducing changes in the expression level of specific genes. Thus, understanding the precise mechanism and the extent of the implication of oxygen tension and ROS in biological events is crucial to maintaining the desired cell and tissue function for application in regenerative medicine strategies. Herein, a comprehensive literature review has been performed to find out the impacts of oxygen tensions on the various behaviors of cells or tissues.
Individuals in this arm will be placed on a wait-list for 12 weeks and will receive no intervention during this time. At the end of the 12 weeks they will receive the On the Move group exercise program. This is a wait-list control group.
BACKGROUND & AIMS: Dementia is accompanied by a variety of changes that result in an increased risk of malnutrition and low-intake dehydration. This guideline update aims to give evidence-based recommendations for nutritional care of persons with dementia in order to prevent and treat these syndromes.
METHODS: The previous guideline version was reviewed and expanded in accordance with the standard operating procedure for ESPEN guidelines. Based on a systematic search in three databases, strength of evidence of appropriate literature was graded by use of the SIGN system. The original recommendations were reviewed and reformulated, and new recommendations were added, which all then underwent a consensus process.
RESULTS: 40 recommendations for nutritional care of older persons with dementia were developed and agreed, seven at institutional level and 33 at individual level. As a prerequisite for good nutritional care, organizations caring for persons with dementia are recommended to employ sufficient qualified staff and offer attractive food and drinks with choice in a functional and appealing environment. Nutritional care should be based on a written care concept with standardized operating procedures. At the individual level, routine screening for malnutrition and dehydration, nutritional assessment and close monitoring are unquestionable. Oral nutrition may be supported by eliminating potential causes of malnutrition and dehydration, and adequate social and nursing support (including assistance, utensils, training and oral care). Oral nutritional supplements are recommended to improve nutritional status but not to correct cognitive impairment or prevent cognitive decline. Routine use of dementia-specific ONS, ketogenic diet, omega-3 fatty acid supplementation and appetite stimulating agents is not recommended. Enteral and parenteral nutrition and hydration are temporary options in patients with mild or moderate dementia, but not in severe dementia or in the terminal phase of life. In all stages of the disease, supporting food and drink intake and maintaining or improving nutrition and hydration status requires an individualized, comprehensive approach. Due to a lack of appropriate studies, most recommendations are good practice points.
CONCLUSION: Nutritional care should be an integral part of dementia management. Numerous interventions are available that should be implemented in daily practice. Future high-quality studies are needed to clarify the evidence.
FIELD: cosmetology. ^ SUBSTANCE: invention is related to the field of application of cosmetic means, in particular individual skin care. Composition for individual care with silicon compound, which is esthetically modified, with salt of quaternary ammonium, where salt has structure AB, in which A represents cation-charged component, B represents anion-charged component, and A has single quaternised atom of nitrogen, at least two hydroxy-groups and molecular weight of not more than 250. Quaternary salt may be represented with hydroxypropyltri (C1-C9-alkyl)ammonium, in particular chloride of dihydroxypropyltrimonium, and silicon is represented in the form of cross-polymer of dimethicon/vinyl dimethicon. Composition is represented in the form of lotion, cream, shampoo, shower gel, antiperspirant, etc. Body parts are moisturised by method of composition application on it. ^ EFFECT: invention provides for moistening of skin with reduced stickiness. ^ 8 cl, 12 tbl, 13 ex
PURPOSE:To provide the subject ink composition containing a coloring material, water and a hydrolyzed keratin (derivative), free from foul smell, having excellent drying resistance on pen point, free from blotting and set-off and resistant to discoloration even on a heat-sensitive paper and carbonless copying paper. CONSTITUTION:The objective water-base ink composition free from foul smell, having excellent drying resistance on pen point, free from blotting and set-off and resistant to discoloration even on a heat-sensitive paper and carbonless copying paper can be produced by compounding a coloring material (e.g. C.I. Acid Red 87) with purified water and a hydrolyzed keratin and/or its derivative as essential components and optionally compounding with a nonionic surfactant (e.g. polyoxyethylene nonylphenyl ether) as a dispersing agent, an antiseptic mildew-proofing agent (e.g. 1,2-benzothiazolin-3-one) as an agent for preventing the block of ink flow caused by the generation of mold and a corrosion inhibitor for metal (e.g. benzotriazole) in the case of using a metal at a part of a writing utensil contacting with the ink.
The triggering receptor expressed on myeloid cells-2 (TREM-2) is an immune receptor expressed on immune and non-immune cells, more frequently investigated in neurodegenerative disorders and considered a marker for microglia activation. In infectious diseases, the receptor was initially believed to be an anti-inflammatory molecule, opposing the inflammation triggered by TREM-1. Currently, TREM-2 is associated with different aspects in response to infectious stimuli, including the induction of bacterial phagocytosis and clearance, containment of exacerbated pro-inflammatory responses, induction of M2 differentiation and activation of Th1 lymphocytes, besides of neurological damage after viral infection. Here, we present and discuss results published in the last two decades regarding the expression, activation and functions of TREM-2 during the course of bacterial, viral, fungal and parasitic infections. A surprisingly plasticity was observed regarding the roles of the receptor in the aforementioned contexts, which largely varied according to the cell/organ and pathogen type, besides influencing disease outcome. Therefore, our review aimed to critically overview the role of TREM-2 in infectious diseases, highlighting its potential to be used as a clinical biomarker or therapeutic target.
Extraskeletal myxoid chondrosarcoma is a rare soft tissue tumour with a high local and distant metastasis rate and limited response to chemotherapy. Meckel's diverticulum is the most frequent congenital anomaly, and it is associated with a considerable risk of malignant transformation. In this case report, we describe a 50-year-old female patient with a history of extraskeletal myxoid chondrosarcoma of the lower limb and metastasis to the forearm who went to the emergency department with abdominal pain. The investigations revealed a caecal volvulus. A lesion in the middle third of the ileum was incidentally discovered and removed during surgery. Pathology examination revealed a Meckel's diverticulum adenocarcinoma, with metastasis of extraskeletal myxoid chondrosarcoma. Resection was complete; however, the patient had diffuse metastatic pulmonary disease and died eight months later due to disease progression. This mechanism of tumour-to-tumour metastasis is described in other locations, but, regarding the Meckel's diverticulum, this is a unique situation, previously unreported in the literature.
Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography.   
Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations.
The invention discloses a traditional Chinese medicine composition for treating renal hematuria. The traditional Chinese medicine composition is prepared from, by weight, 10-60 parts of dried rehamnnia roots, 5-30 parts of semen plantaginis, 3-20 parts of lophatherum gracile, 10-45 parts of lalang grass rhizome, 5-30 parts of talc, 0.3-3 parts of rush and 5-30 parts of teucrium viscidum. The traditional Chinese medicine composition can be used for preparing a conventional oral preparation through the conventional preparation technology. The traditional Chinese medicine composition is definite in curative effect, small in toxic and side effect and remarkable and curable in clinical hematuria treating effect. The invention further discloses a preparation method of the traditional Chinese medicine composition for treating the renal hematuria. The preparation method can prepare the traditional Chinese medicine composition with the stable quality and curative effect.
Use of mogrosides or pharmaceutically acceptable salts thereof in the manufacture of a tumor radiation sensitizing agent. Preferably the mogrosides have the following general structure: wherein, R and R1 are glucose residues. More preferably, the mogroside is mogroside II, mogroside III, mogroside IV, mogroside V or mogroside VI. The radiation sensitizing agent may comprise the mogroside and an acceptable carrier, wherein the acceptable carrier is a compatible solid, liquid filler or gel substance. The tumor sensitizing agent may up-regulate the expression of anti-cancer P53 gene and/or down-regulate the expression of Bcl-2 protein. Preferably the tumor is selected from liver, lung or cervical cancer. The tumour radiation sensitizing agent may increase the sensitivity of tumors to radiotherapy while the side effects of radiation therapy can be reduced.